PROTEOMICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	4/29/2001 5:17:29 PM
From: nigel bates	Read Replies (1) of 539

Genomeweb article on the Myriad proteomics effort - genomeweb.com "Their technical approach is focused on the structural interactions between pairs of proteins, rather than changes in protein amounts that are the basis of disease and drug effects," said Leigh Anderson, CEO of Large Scale Proteomics, a Gaithersburg, Md.-based subsidiary of Large Scale Biology that is studying protein expression levels. "Hence the Myriad deal only covers one niche in the human proteome, and one that we would argue is clearly of secondary interest in comparison to expression." But Myriad scientists responded that they already have an idea of which genes or proteins are associated with particular diseases, and that mapping out the interactions of these proteins will allow them to identify proteins more promising as drug targets...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next